Credits Available: 3.50 AMA PRA Category 1 Credit

Description: Chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide, is a heterogeneous lung condition characterized by chronic respiratory symptoms caused by persistent airflow limitation due to airway and alveolar abnormalities. Initial COPD management relies on bronchodilators with the addition of inhaled corticosteroids for those at high risk for exacerbations. However, up to half of patients on triple therapy still experience exacerbations, highlighting a need for new therapies. Biologic therapy targeting type 2 inflammation, which is common in COPD and associated with exacerbation risk, has recently been approved for clinical use as add-on maintenance treatment of adult patients with inadequately controlled COPD and an eosinophilic phenotype. This educational program is designed to get pulmonology experts up to date on these rapid treatment advances for COPD as well as to bolster standard-of-care fundamentals.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Pulmonary/Respiratory Physician

Anita Kohli-Pamnani

Allergy, Asthma & Immunology
Physician/Assistant Clinical Professor

I'm an Adult and Pediatric Allergist Immunologist with 20 years of community private practice and academic experience as Assistant Clinical Professor.